STAT+: AI titans push Congress for DNA safeguards
Why this matters: health reporting relevant to everyday decisions and well-being.
Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. The inventor of some of AI’s technical underpinnings is shifting focus to an RNA startup. Also, Rick Pazdur has some ideas on how to determine whether Revolution Medicines’ pancreatic cancer drug can work in a first-line setting. And an oncologist explains why she believes the failed Grail trial matters. The AI architect taking aim at RNAi&#x A0; Jakob Uszkoreit helped create the transformer architecture — the “T” in ChatGPT — that sparked the generative AI boom. Now he’s trying to do something just as ambitious in drug development, STAT’s Brittany Trang writes. His startup, Inceptive Nucleics, is building biological foundation models that can be applied across a wide range of sequence-based medicines, from RNA interference therapies to mRNA and antisense drugs.Continue to STAT+ to read the full story…